This ‘Presbyopia - China Market Insight, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trend in China.
The Presbyopia market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted China Presbyopia market size from 2019 to 2032. The Report also covers current Presbyopia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Presbyopia is a normal part of aging wherein your eyes gradually lose the ability to see things up close. The term “presbyopia” comes from a Greek word that means “old eye.” Most people begin to notice the effect of presbyopia sometime after the age of 40 as the lenses of the eyes naturally lose their elasticity due to the aging process.
It is mostly due to age-related changes that the proteins within the lens of the eye become thicker, harder, and less flexible. This loss of flexibility affects the lens's ability to refract light rays which, in turn, affects the eye's capacity to focus. Age is the major risk factor for the development of presbyopia along with factors like trauma, systemic disease, cardiovascular disease, or a drug side effect. According to type, Presbyopia can be classified into incipient presbyopia, functional presbyopia, absolute presbyopia, premature presbyopia, and nocturnal presbyopia
Initial symptoms include difficulties with prolonged close-up work along with tiring of the eyes. Other common symptoms are delays in focusing at near or distance, ocular discomfort, headache, asthenopia, squinting, fatigue or drowsiness from near work, increased working distance, need for brighter light for reading, and diplopia. This may progress to blurred vision when looking at objects close up and to headaches and eye strain when attempting close work.
A basic and comprehensive examination of the eye with a series of different tests is necessary to diagnose presbyopia. The ophthalmologist examines the retina and conducts muscle integrity, refraction, slit-lamp, visual field, and visual acuity tests. These will help to ascertain the condition. Eye drops used during this process to dilate the pupils will cause patients to experience increased sensitivity to light in the few hours following the examinations.
With the help of an ophthalmoscope, the specialist can evaluate the retina, optic disk, and choroid (i.e. a layer of blood vessels responsible for providing nourishment to the retina). A muscle integrity test is done with a moving object, and the ability to follow this object is evaluated. Refractive tests assess how well light waves are bent as they go through the cornea and the lens and the results of these tests help to determine which lens prescription will be needed. Presbyopia cannot be prevented as it is an inevitable part of aging.
Presbyopia Treatment
The goal of treatment is to compensate for the inability of your eyes to focus on nearby objects. Treatment includes wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia. Most clinical management of presbyopia includes nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, or some other tempering agents. The commonly used off-label ophthalmic drops have pilocarpine, carbachol, aceclidine, brimonidine, and nepafenac as their main ingredient. They target the ciliary muscles and change the pupil size and elasticity thereby improving the near vision. Recently the US FDA approved Vuity developed by AbbVie for the treatment of presbyopia in adults. However, there are currently no approved presbyopia-correcting therapeutics in China. There is a high unmet need for new therapies to treat presbyopia. To fill the unmet gap, several companies are conducting clinical trials to investigate new treatment options, and some interesting therapies are heading down the pipeline.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Presbyopia, total diagnosed cases of Presbyopia, total age-specific cases of Presbyopia, gender-specific cases of Presbyopia, and severity-specific cases of Presbyopia scenario of Presbyopia in China from 2019 to 2032.
The epidemiology segment provides the Presbyopia epidemiology data and findings for China.
The drug chapter segment of the Presbyopia report encloses the detailed analysis of Presbyopia marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Presbyopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
ARVN003 (Microline): Arctic Vision and Eyenovia
ARVN003 (known as MicroLine in the US) of Eyenovia is a patented micro-dosed pilocarpine formulation distributed through the Optejet dispenser of the Business. Pilocarpine works by creating a Pinhole effect, which is done by the constricting of the pupil of the eye, similar to a pinhole camera, and brings near and medium-distance objects into focus. The drug is presently being evaluated in phase III (VISION -2) to determine the safety and efficacy of 2% pilocarpine ophthalmic spray in adults with presbyopia.
In 2020 Arctic Vision received an exclusive license from Eyenovia for the development and commercialization of ARVN003 (MicroLine) in Greater China and South Korea, and in 2021 it received IND clearance from the Center for Drug Evaluation, China National Medical Products Administration (CDE, NMPA) for a Phase III study of ARVN003 (pilocarpine microdose ophthalmic solution) for the treatment of presbyopia. It is the first clinical trial to be approved in China for presbyopia treatment.
Brimochol PF and Carbachol PF: Zhaoke Ophthalmology Limited and Visus Therapeutics
Brimochol PF (VT-101) and Carbachol PF of Visus Therapeutics are pupil-modulating eye drops that are meant to be once-daily, preservative-free therapies for the correction of presbyopia-related loss of near vision. Brimochol PF is carbachol (a cholinergic agent) and brimonidine tartrate fixed-dose combination (an alpha-2 agonist). Carbachol PF is a patented carbachol monotherapy formulation that is free of preservatives. Both investigational therapies reduce the pupil, creating a "pinhole effect" that allows only centrally directed light rays to enter the eye, intensifying near and intermediate image treatment. The drug is presently being evaluated in phase III (BRIO-I and BRIO-II) to determine the safety and efficacy of Brimochol PF and Carbachol PF for the treatment of presbyopia.
In May 2022, Visus Therapeutics and Zhaoke Ophthalmology signed an exclusive licensing agreement for the development and commercialization of Brimochol PF and Carbachol PF in Greater China, South Korea, and select Southeast Asian territories, with Zhaoke Ophthalmology responsible for clinical development, regulatory approval, and product commercialization in the said territories.
LNZ100 (aceclidine) & LNZ101 (aceclidine + brimonidine): Ji Xing Pharmaceuticals and LENZ Therapeutics
LNZ100, a 1.75% aceclidine formulation being developed by LENZ Therapeutics, is the first and only aceclidine-based eye drop to provide a seamless vision for the vast majority of all presbyopes. While LNZ101 is a combination of 1.75% aceclidine with brimonidine for the treatment of presbyopia with the potential for increased duration of treatment and an added advantage of eye whitening. Both formulations use a proprietary, preservative-free vehicle matrix to maximize comfort, efficiency, and bioavailability. LENZ therapeutics plans to start its pivotal Phase III trial in the second half of 2022.
LENZ Therapeutics and Ji Xing Pharmaceuticals signed an exclusive license agreement in April 2022 to develop and market LNZ100 and LNZ101 for the treatment of presbyopia in Greater China.
List of products to be continued in the report…
Despite decades of research, treatment options for Presbyopia are restricted. The goal of treatment is to compensate for the inability of the eyes to focus on nearby objects.
Current treatment options are typically device or surgery-based, such as reading glasses, contact lenses, corneal procedures, and multifocal intraocular lens implantation. Presbyopia cannot be cured, but properly prescribed glasses or contact lenses can make seeing up close much more comfortable. Though reading glasses are the most common solution for near-vision correction, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons.
There are currently no approved presbyopia-correcting therapeutics in China. Vuity (AGN-190584), developed by Allergan (which was acquired by AbbVie), is a miotic 1.25% pilocarpine hydrochloride ophthalmic solution, is the first and only FDA-approved eye drop to treat presbyopia, an eye condition that affects nearly half of the US adult population. The approval was based on results from two pivotal Phase III studies, GEMINI 1 and GEMINI 2, which demonstrated the drugs' effectiveness in improving near and intermediate vision without impacting distance vision using the eye's own ability to reduce the pupil size. The company might also plan to launch this drug in China for the treatment of presbyopia.
There is a high unmet need for new therapies to treat presbyopia. To fill the unmet gap, several companies are conducting clinical trials to investigate new treatment options, and some interesting therapies are heading down the pipeline. Key players such as Arctic Vision and Eyenovia (ARVN003/MicroLine), Visus therapeutics and Zhaoke Ophthalmology (Brimochol PF and Carbachol PF), Lenz Therapeutics and JiXing (LNZ100 and LNZ101), Ocuphire Pharma (Nyxol), Novartis (UNR844), Allergan (acquired by AbbVie) (AGN-241622), Orasis Pharmaceuticals (CSF-1/PresbiDrops), and others are investigating their candidates for the management of presbyopia in China.
According to the publisher, the treatment space for Presbyopia will experience a significant impact in the coming years due to the launch of new therapies and a rise in healthcare spending across the world.
This section provides the total Presbyopia market size and market size by therapies in China.
This section focuses on the rate of uptake of the potential drugs recently launched in the Presbyopia market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Presbyopia market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allow, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.
The report covers detailed information on collaborations, acquisitions, and mergers, licensing, and patent details for Presbyopia emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
The publisher performs competitively and market Intelligence analysis of the Presbyopia market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
The Presbyopia market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted China Presbyopia market size from 2019 to 2032. The Report also covers current Presbyopia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- China
Presbyopia Disease Understanding and Treatment Algorithm
Presbyopia Overview
Presbyopia is a normal part of aging wherein your eyes gradually lose the ability to see things up close. The term “presbyopia” comes from a Greek word that means “old eye.” Most people begin to notice the effect of presbyopia sometime after the age of 40 as the lenses of the eyes naturally lose their elasticity due to the aging process.
It is mostly due to age-related changes that the proteins within the lens of the eye become thicker, harder, and less flexible. This loss of flexibility affects the lens's ability to refract light rays which, in turn, affects the eye's capacity to focus. Age is the major risk factor for the development of presbyopia along with factors like trauma, systemic disease, cardiovascular disease, or a drug side effect. According to type, Presbyopia can be classified into incipient presbyopia, functional presbyopia, absolute presbyopia, premature presbyopia, and nocturnal presbyopia
Initial symptoms include difficulties with prolonged close-up work along with tiring of the eyes. Other common symptoms are delays in focusing at near or distance, ocular discomfort, headache, asthenopia, squinting, fatigue or drowsiness from near work, increased working distance, need for brighter light for reading, and diplopia. This may progress to blurred vision when looking at objects close up and to headaches and eye strain when attempting close work.
Presbyopia Diagnosis
A basic and comprehensive examination of the eye with a series of different tests is necessary to diagnose presbyopia. The ophthalmologist examines the retina and conducts muscle integrity, refraction, slit-lamp, visual field, and visual acuity tests. These will help to ascertain the condition. Eye drops used during this process to dilate the pupils will cause patients to experience increased sensitivity to light in the few hours following the examinations.
With the help of an ophthalmoscope, the specialist can evaluate the retina, optic disk, and choroid (i.e. a layer of blood vessels responsible for providing nourishment to the retina). A muscle integrity test is done with a moving object, and the ability to follow this object is evaluated. Refractive tests assess how well light waves are bent as they go through the cornea and the lens and the results of these tests help to determine which lens prescription will be needed. Presbyopia cannot be prevented as it is an inevitable part of aging.
Presbyopia Treatment
The goal of treatment is to compensate for the inability of your eyes to focus on nearby objects. Treatment includes wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia. Most clinical management of presbyopia includes nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, or some other tempering agents. The commonly used off-label ophthalmic drops have pilocarpine, carbachol, aceclidine, brimonidine, and nepafenac as their main ingredient. They target the ciliary muscles and change the pupil size and elasticity thereby improving the near vision. Recently the US FDA approved Vuity developed by AbbVie for the treatment of presbyopia in adults. However, there are currently no approved presbyopia-correcting therapeutics in China. There is a high unmet need for new therapies to treat presbyopia. To fill the unmet gap, several companies are conducting clinical trials to investigate new treatment options, and some interesting therapies are heading down the pipeline.
Presbyopia Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Presbyopia, total diagnosed cases of Presbyopia, total age-specific cases of Presbyopia, gender-specific cases of Presbyopia, and severity-specific cases of Presbyopia scenario of Presbyopia in China from 2019 to 2032.
Key Findings
- According to the publisher analysis, China accounted for 329,861,640 Presbyopia prevalent cases in the year 2021. These cases are expected to grow by the year 2032.
- China accounted for 282,919,791 Presbyopia diagnosed cases in the year 2021, which are expected to rise by the year 2032.
- In China, the total age-specific cases of Presbyopia were 77,066,373, 107,043,777, 67,159,677, and 31,649,963 cases for the age group 40-49 years, 50-59 years, 60-69 years, and ≥70 years, respectively in the year 2021. These cases are expected to rise significantly by 2032.
- In China, the total gender-specific cases of Presbyopia were 124,155,342 and 158,764,448 cases for males and females, respectively in the year 2021.
- In China, the total severity-specific cases of Presbyopia were 84,875,937 and 198,043,854 cases for mild cases and moderate to severe cases, respectively in the year 2021.
Presbyopia Epidemiology
The epidemiology segment provides the Presbyopia epidemiology data and findings for China.
Presbyopia Drug Chapters
The drug chapter segment of the Presbyopia report encloses the detailed analysis of Presbyopia marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Presbyopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
Presbyopia Emerging Drugs
ARVN003 (Microline): Arctic Vision and Eyenovia
ARVN003 (known as MicroLine in the US) of Eyenovia is a patented micro-dosed pilocarpine formulation distributed through the Optejet dispenser of the Business. Pilocarpine works by creating a Pinhole effect, which is done by the constricting of the pupil of the eye, similar to a pinhole camera, and brings near and medium-distance objects into focus. The drug is presently being evaluated in phase III (VISION -2) to determine the safety and efficacy of 2% pilocarpine ophthalmic spray in adults with presbyopia.
In 2020 Arctic Vision received an exclusive license from Eyenovia for the development and commercialization of ARVN003 (MicroLine) in Greater China and South Korea, and in 2021 it received IND clearance from the Center for Drug Evaluation, China National Medical Products Administration (CDE, NMPA) for a Phase III study of ARVN003 (pilocarpine microdose ophthalmic solution) for the treatment of presbyopia. It is the first clinical trial to be approved in China for presbyopia treatment.
Brimochol PF and Carbachol PF: Zhaoke Ophthalmology Limited and Visus Therapeutics
Brimochol PF (VT-101) and Carbachol PF of Visus Therapeutics are pupil-modulating eye drops that are meant to be once-daily, preservative-free therapies for the correction of presbyopia-related loss of near vision. Brimochol PF is carbachol (a cholinergic agent) and brimonidine tartrate fixed-dose combination (an alpha-2 agonist). Carbachol PF is a patented carbachol monotherapy formulation that is free of preservatives. Both investigational therapies reduce the pupil, creating a "pinhole effect" that allows only centrally directed light rays to enter the eye, intensifying near and intermediate image treatment. The drug is presently being evaluated in phase III (BRIO-I and BRIO-II) to determine the safety and efficacy of Brimochol PF and Carbachol PF for the treatment of presbyopia.
In May 2022, Visus Therapeutics and Zhaoke Ophthalmology signed an exclusive licensing agreement for the development and commercialization of Brimochol PF and Carbachol PF in Greater China, South Korea, and select Southeast Asian territories, with Zhaoke Ophthalmology responsible for clinical development, regulatory approval, and product commercialization in the said territories.
LNZ100 (aceclidine) & LNZ101 (aceclidine + brimonidine): Ji Xing Pharmaceuticals and LENZ Therapeutics
LNZ100, a 1.75% aceclidine formulation being developed by LENZ Therapeutics, is the first and only aceclidine-based eye drop to provide a seamless vision for the vast majority of all presbyopes. While LNZ101 is a combination of 1.75% aceclidine with brimonidine for the treatment of presbyopia with the potential for increased duration of treatment and an added advantage of eye whitening. Both formulations use a proprietary, preservative-free vehicle matrix to maximize comfort, efficiency, and bioavailability. LENZ therapeutics plans to start its pivotal Phase III trial in the second half of 2022.
LENZ Therapeutics and Ji Xing Pharmaceuticals signed an exclusive license agreement in April 2022 to develop and market LNZ100 and LNZ101 for the treatment of presbyopia in Greater China.
List of products to be continued in the report…
Presbyopia Market Outlook
Despite decades of research, treatment options for Presbyopia are restricted. The goal of treatment is to compensate for the inability of the eyes to focus on nearby objects.
Current treatment options are typically device or surgery-based, such as reading glasses, contact lenses, corneal procedures, and multifocal intraocular lens implantation. Presbyopia cannot be cured, but properly prescribed glasses or contact lenses can make seeing up close much more comfortable. Though reading glasses are the most common solution for near-vision correction, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons.
There are currently no approved presbyopia-correcting therapeutics in China. Vuity (AGN-190584), developed by Allergan (which was acquired by AbbVie), is a miotic 1.25% pilocarpine hydrochloride ophthalmic solution, is the first and only FDA-approved eye drop to treat presbyopia, an eye condition that affects nearly half of the US adult population. The approval was based on results from two pivotal Phase III studies, GEMINI 1 and GEMINI 2, which demonstrated the drugs' effectiveness in improving near and intermediate vision without impacting distance vision using the eye's own ability to reduce the pupil size. The company might also plan to launch this drug in China for the treatment of presbyopia.
There is a high unmet need for new therapies to treat presbyopia. To fill the unmet gap, several companies are conducting clinical trials to investigate new treatment options, and some interesting therapies are heading down the pipeline. Key players such as Arctic Vision and Eyenovia (ARVN003/MicroLine), Visus therapeutics and Zhaoke Ophthalmology (Brimochol PF and Carbachol PF), Lenz Therapeutics and JiXing (LNZ100 and LNZ101), Ocuphire Pharma (Nyxol), Novartis (UNR844), Allergan (acquired by AbbVie) (AGN-241622), Orasis Pharmaceuticals (CSF-1/PresbiDrops), and others are investigating their candidates for the management of presbyopia in China.
According to the publisher, the treatment space for Presbyopia will experience a significant impact in the coming years due to the launch of new therapies and a rise in healthcare spending across the world.
Key Findings
- The market size of Presbyopia in China was USD 14,375 million in 2021, which is further expected to increase by 2032.
- The expected launch of new potential therapies may increase market size in the coming years, assisted by an increase in the prevalent population of Presbyopia.
- Upcoming therapies such as ARVN003, Brimochol PF, and others have the potential to create a significant positive shift in the Presbyopia market size in near future.
China Market Outlook
This section provides the total Presbyopia market size and market size by therapies in China.
Presbyopia Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Presbyopia market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Presbyopia market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allow, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Presbyopia Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers detailed information on collaborations, acquisitions, and mergers, licensing, and patent details for Presbyopia emerging therapies.
Reimbursement Scenario in Presbyopia
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
The publisher performs competitively and market Intelligence analysis of the Presbyopia market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Presbyopia, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the Presbyopia epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Presbyopia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Presbyopia market; historical and forecasted is included in the report, covering China's drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the China Presbyopia market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the Presbyopia market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Presbyopia. The launch of emerging therapies will significantly impact the Presbyopia market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Presbyopia Report Insights
- Patient Population
- Therapeutic Approaches
- Presbyopia Pipeline Analysis
- Presbyopia Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Presbyopia Report Key Strengths
- 11-Years Forecast
- China Coverage
- Presbyopia Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Presbyopia Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Key Questions
Market Insights:
- What was the Presbyopia market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Presbyopia total market size as well as market size by therapies in China during the forecast period (2022-2032)?
- At what CAGR, the Presbyopia market is expected to grow in China during the forecast period (2022-2032)?
- What would be the Presbyopia market outlook for China during the forecast period (2022-2032)?
- What would be the Presbyopia market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burdens, and unmet needs of Presbyopia?
- What is the historical Presbyopia patient pool for China?
- What would be the forecasted patient pool of Presbyopia for China?
- What will be the growth opportunities for China with respect to the patient population pertaining to Presbyopia?
- Out of the above-mentioned countries, which country would have the highest incidence population of Presbyopia during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow for China during the forecast period (2022-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Presbyopia along with the approved therapy?
- What are the current treatment guidelines for the treatment of Presbyopia in China?
- What are the Presbyopia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Presbyopia?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Presbyopia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the Presbyopia therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Presbyopia and their status?
- What are the key designations that have been granted for the emerging therapies for Presbyopia?
- What is China's historical and forecasted market of Presbyopia?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving Presbyopia.
- To understand the future market competition in the Presbyopia market and an Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Presbyopia in China.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Presbyopia market.
- To understand the future market competition in the Presbyopia market.
Table of Contents
1. Key Insights2. Report Introduction4. Executive Summary of Presbyopia5. Key Events8. Early Detection and Prevention of Presbyopia10. Guidelines of Presbyopia12. Patient Journey15. Key Opinion Leaders’ Views16. Market Drivers17. Market Barriers18. SWOT Analysis19. Unmet Needs21. Publisher Capabilities22. Disclaimer23. About the Publisher
3. Presbyopia Market Overview at a Glance
6. Disease Background and Overview
7. Diagnosis of Presbyopia
9. Current Treatment Practices: Presbyopia
11. Epidemiology and Patient Population
13. Emerging Drugs
14. Presbyopia: China Market Analysis
20. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Arctic Vision and Eyenovia
- Visus therapeutics and Zhaoke Ophthalmology
- Lenz Therapeutics and JiXing
- Novartis
- Orasis Pharmaceuticals
- Ocuphire Pharma
- Glaukos Corporation
- AbbVie
